11,013 Shares in GeneDx Holdings Corp. $WGS Acquired by EFG Asset Management North America Corp.

Key Points

• EFG Asset Management North America Corp. made a new investment of $975,000 in GeneDx Holdings Corp., acquiring 11,013 shares according to a recent SEC filing.
• GeneDx reported earnings of $0.50 per share for the last quarter, exceeding estimates and generating revenue of $102.69 million.
• Insider trading activity revealed significant sales by key directors, with over $67.5 million worth of shares sold in the past 90 days, indicating potential shifts in company ownership dynamics.

EFG Asset Management North America Corp. acquired a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 11,013 shares of the company's stock, valued at approximately $975,000.

Several other large investors also recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. bought a new position in shares of GeneDx during the fourth quarter valued at approximately $2,645,000. Raymond James Financial Inc. grew its stake in shares of GeneDx by 25.8% during the first quarter. Raymond James Financial Inc. now owns 333,376 shares of the company's stock valued at $29,525,000 after buying an additional 68,331 shares during the last quarter. Voya Investment Management LLC bought a new position in shares of GeneDx during the fourth quarter valued at approximately $292,000. GAMMA Investing LLC grew its stake in shares of GeneDx by 22,194.3% during the first quarter. GAMMA Investing LLC now owns 38,792 shares of the company's stock valued at $3,436,000 after buying an additional 38,618 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of GeneDx by 111.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 190,297 shares of the company's stock valued at $16,097,000 after buying an additional 100,146 shares during the last quarter. 61.72% of the stock is owned by institutional investors.

Insider Buying and Selling at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 378 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $125.81, for a total transaction of $47,556.18. Following the completion of the transaction, the chief financial officer directly owned 4,096 shares of the company's stock, valued at $515,317.76. This trade represents a 8.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Casdin Capital, Llc sold 500,000 shares of GeneDx stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $120.90, for a total transaction of $60,450,000.00. Following the completion of the sale, the director owned 3,007,164 shares in the company, valued at approximately $363,566,127.60. This represents a 14.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 561,641 shares of company stock worth $67,551,904 over the last three months. 29.60% of the stock is currently owned by insiders.

GeneDx Stock Performance

NASDAQ WGS traded down $3.21 during trading on Monday, reaching $129.33. The company's stock had a trading volume of 442,296 shares, compared to its average volume of 658,089. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87. The firm has a market cap of $3.72 billion, a price-to-earnings ratio of 2,586.60 and a beta of 2.03. GeneDx Holdings Corp. has a twelve month low of $32.11 and a twelve month high of $136.00. The business's fifty day moving average price is $104.92 and its 200-day moving average price is $91.12.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The business had revenue of $102.69 million for the quarter, compared to analyst estimates of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. As a group, analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on WGS shares. Piper Sandler set a $120.00 price target on GeneDx and gave the company an "overweight" rating in a report on Monday, August 4th. Wells Fargo & Company boosted their price target on GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, July 30th. Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Guggenheim reiterated a "buy" rating and issued a $115.00 price target (up previously from $88.00) on shares of GeneDx in a report on Monday, June 30th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, GeneDx currently has an average rating of "Moderate Buy" and a consensus target price of $101.63.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.